of the biologic agents currently utilized in the United States for this indication (adalimumab, alefacept, efalizumab, etanercept and infliximab). Model results were displayed for a time horizon of one year based on a switch to an appropriate alternate biologic agent in the event of suboptimal clinical response. Multiple oneway sensitivity analyses were conducted. RESULTS: Across all the biologics evaluated there are significant differences in PASI 75 response at 12 weeks versus longer term (ranging from 59% to 20% across the agents at the end of one quarter of treatment and at the end of four quarters of treatment, respectively). The cost per PASI 75 was observed to be $26,460, $31,191, $28,217, $30,544 and $30,983 for therapy initiated with adalimumab, alefacept, efalizumab, etanercept and infliximab, respectively. CONCLUSION: While there are significant differences in the cost of the studied biologic agents initially, the CE results tend to converge over the first year of treatment. Further research needs to be conducted to evaluate the CE of treatment beyond a oneyear period. In western countries AMD is considered one of the most important causes of blindness among persons over 65 years old. The purpose of this study was to determine the costeffectiveness of pegaptanib vs verteporfin in the treatment of AMD from the health care payer's perspective. METHODS: A seven-stage stochastic Markov model based on visual acuity (VA) in the better seeing-eye (stages: with clinical benefit, VA>20/40; VA:20/40-20/; VA:20/100-20/160; VA:20/200-20/500; VA < 20/ 500 and legal blindness) was performed during a five-year period. Effectiveness measure used in the assessment was the probability to gain at least one-level of VA at the end of the follow up period. Effectiveness data was obtained from international published literature. Comparators used in the model were pegaptanib 0.3 mg (8 sessions) and verteporfin 15 mg (10 sessions). Resource use and cost data were obtained from hospital records and official institutional databases from the Social Security Mexican Institute (IMSS). Costs and health outcomes were discounted with a 3% annual rate. The model was calibrated. Probabilistic sensitivity analyses were performed to determine the results robustness. RESULTS: Patients who received pegaptanib experienced a higher probability to gain at least one level of VA(57.4%; CI95%:52.26%-62.54%) compared with patients treated with verteporfin (13.8%; IC95%:10.61%-16.99%) considering an initial VA state of ">20/40"(p < 0.001). Mean total costs per patient were higher in patients who received pegaptanib compared to those who received verteporfin (US$6749; CI95%:US$6401-US$7096 vs. US$6311 CI95%:US$5948-US$6674; respectively). The ICER in patients receiving pegaptanib compared to those receiving verteporfin was US$1004 (CI95% US$926-US$1090). Sensitivity analyses found that pegaptanib is a cost-saving strategy when the numbers of sessions given to the patients are less than three. CONCLUSION: The results show that in Mexico, pegaptanib is a cost-effective therapy for AMD when is compared with verteporfin. These results should be taken into account by Mexican decision makers in the management of patients with AMD. is a disease characterized by inflammation of the eye lid, conjunctiva and cornea and is typically treated empirically with topical antibiotic/ anti-inflammatory agents. The purpose of this study was to compare the cost-effectiveness of tobramycin 0.3%/loteprednol 0.5%, (Zylet) to tobramycin 0.3%/dexamethasone 0.1%, (Tobradex) for the rapid control of BKC. METHODS: Effectiveness data for this analysis came from a randomized, double-masked, parallel-group study of forty patients with BKC. Patients were treated with either Zylet™ or Tobradex® administered twice daily in the test eye. The measure of effectiveness used was the change in a clinical composite score of four BKC components: blepharitis, ocular discharge, conjunctivitis, and corneal punctuate epithelial keratopathy (PEK). Each clinical component was graded on a scale of 0 (minimum) to three (extensive) and assessed at baseline and on day 4 (Ϯ1) of therapy. Five different pharmacy chains were surveyed as to their prices for a 5ml bottle of both Tobradex and Zylet. The average price of each agent was used as the cost measure in the analysis. A probabilistic sensitivity analysis evaluated the robustness of the economic outcomes. The economic perspective was that of the payer. Due to the short time span no cost discounting was performed. RESULTS: Reductions in the BKC clinical composite scores at the day-4 assessment were calculated at 4.5 (SD Ϯ 1.7) versus 7.1 (SD Ϯ 1.2) for the Zylet and Tobradex groups, respectively. The average retail costs for Zylet and Tobradex were $96.45 (SD Ϯ $5.26) and $71.75 (SD Ϯ $5.48) respectively. The cost-effectiveness ratios for Zylet and Tobradex therapy were $21.43 and $10.10, respectively. The cost-effectiveness results remained consistent using the probabilistic sensitivity distributions tested. CONCLUSION: Tobradex economically dominated Zylet for the rapid control of BKC because it was both less costly and more effective.
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PSS20 COST-EFFECTIVENESS OF TOBRADEX VERSUS ZYLET FOR THE TREATMENT OF BLEPHAROKERATOCONJUNCTIVITIS

PSS21 COST OF ILLNESS OF WORK-RELATED CHRONIC HAND ECZEMA IN GERMANY
Diepgen T 1 , Hieke K 2 1 University Hospital Heidelberg, Heidelberg, Germany, 2 NEOS Health (a COPERA company), Binningen, Switzerland OBJECTIVE: In Germany, 26% of reported and 36% (= 8'460) of confirmed work-related diseases are skin-related, in over 90% of these cases hands are affected. However, there is a lack on comprehensive information on costs associated with chronic hand eczema (CHE). The objective of this study was to assess the direct and indirect costs of CHE. METHODS: Data on 151 Patients with occupational skin diseases entering a special rehabilitation program were assessed for the preceding 12 months. Data were derived from patient records and direct patient information. Descriptive analyses from a societal perspective was performed for all patients and by physician-rated severity (severity group 1: no/mild; group 2: moderate/severe). DGUV (German Statutory Accident Insurance) was the payer for all patients. RESULTS: Mean age was 44.9 years, 64.9% of patients were male. Total mean annual costs amounted to €8.160 (95% CI: 6.395-9.925) per patient. Indirect costs represented 75% of total costs, in-patient-rehabilitation 14%. Each other factor (out-patient services, diagnostics, drugs, complementary therapies, out-of-pocket expenses) contributed < 3% to overall costs. Disease severity influenced QoL significantly (DLQI-score of severity group 1: 7.9,
A290
Abstracts
